Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. BDRX
BDRX logo

BDRX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BDRX News

Biodexa Supports Life's a Polyp Foundation for FAP Patients

1d agoNewsfilter

Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment

Feb 04 2026Newsfilter

Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%

Jan 05 2026NASDAQ.COM

B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading

Dec 16 2025Benzinga

Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading

Dec 09 2025Benzinga

Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP

Nov 24 2025Newsfilter

Biodexa Pharmaceuticals submits $100M shelf registration for versatile securities sales

Sep 26 2025SeekingAlpha

Biodexa Pharmaceuticals Reports GAAP EPS of £0.00

Sep 12 2025SeekingAlpha

Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Receives Upgrade to Buy: Implications for the Stock

Sep 03 2025NASDAQ.COM

Biodexa Reports Enrollment of Initial Patients in Key Phase 3 Serenta Trial for Familial Adenomatous Polyposis (FAP)

Aug 18 2025Newsfilter

ADR Ratio Change Effective

Jul 31 2025Newsfilter

Upcoming Stock Splits This Week (July 28 to August 1) – Stay Invested

Jul 27 2025TipRanks

ADR Ratio Change

Jul 15 2025Newsfilter

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14 2025Newsfilter

Results of Annual General Meeting

Jun 27 2025Newsfilter

Biodexa Pharmaceuticals PLC Announces Successful Outcome of Annual General Meeting

Jun 27 2025NASDAQ.COM